Mechanisms of neuroprotective effects of therapeutic acetylcholinesterase inhibitors used in treatment of Alzheimer's disease

Yakugaku Zasshi

Volumn 126, Issue 8, 2006, Pages 607-616

  Takatori, Yuki ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Cortical culture; Glutamate; Neurotoxicity; Nicotinic acetylcholine receptor

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; CHOLINESTERASE INHIBITOR; DIHYDRO BETA ERYTHROIDINE; DONEPEZIL; GALANTAMINE; GLUTAMIC ACID; MECAMYLAMINE; METHYLLYCACONITINE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NICOTINIC RECEPTOR; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; SCOPOLAMINE; TACRINE;

ALZHEIMER DISEASE; APOPTOSIS; DRUG EFFECT; DRUG MECHANISM; IC 50; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; REVIEW;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ALZHEIMER DISEASE; ANIMALS; CELL DEATH; CELLS, CULTURED; CEREBRAL CORTEX; CHOLINESTERASE INHIBITORS; GALANTAMINE; GLUTAMATES; HUMANS; INDANS; NEURONS; NEUROPROTECTIVE AGENTS; PIPERIDINES; RATS; RECEPTORS, NICOTINIC; TACRINE;

EID: 33746808620     PISSN: 00316903     EISSN: 13475231     Source Type: Journal    
DOI: 10.1248/yakushi.126.607     Document Type: Review

References (24)

1. Whitehouse P. J., Price D. L., Struble R. G., Science, 215, 1237-1239 (1982).
2. Perry E. K., Morris C. M., Court J. A., Cheng A., Fairbairn A. F., McKeith I. G., Irving D., Brown A., Perry R. H., Neuroscience, 64, 385-395 (1995).
3. Bartus R. T., Dean III R. L., Beer B., Lippa A. S., Science, 217, 408-414 (1982).
4. Coyle J. T., Price D. L., DeLong M. R., Science, 219, 1184-1190 (1983).
5. Kosasa T., Yamanishi Y., Ogura H., Yamatsu K., Eur. J. Pharmacol., 183, Abst: 1936 (1990).
6. Bresnick G. H., Arch. Ophthalmol., 107, 339-341 (1989).
7. Choi D. W., Maulucci-Gedde M., Kriegstein A., J. Neurosci., 7, 357-368 (1987).
8. Koh J. Y., Yang L. L., Cotman C. W., Brain Res., 553, 315-320 (1990).
9. Le W. D., Colom L. V., Xie W. J., Smith R. G., Alexianu M., Appel S. H., Brain Res., 686, 49-60 (1995).
10. Pearson R. C., Esiri M. M., Hiorns R. W., Wilcock G. K., Powell T. P., Proc. Natl. Acad. Sci. U.S.A., 82, 4531-4534 (1985).
11. Fransis R. T., Sims N. R., Procter A. W., Bowen D. M., J. Neurochem., 60, 1589-1604 (1993).
12. Mattson M. P., Natl. Rev. Mol. Cell Biol., 1, 120-129 (2000).
13. Kerr J. F., Harmon B. V., Curr. Commun. Cell Mol. Biol., 3, 5-29 (1991).
14. Schwartz L. M., Smith S. W., Jones M. E., Osborne B. A., Proc. Natl. Acad. Sci. U.S.A., 90, 980-984 (1993).
15. Kerr J. F., Wyllie A. H., Currie A. R., Br. J. Cancer, 26, 239-257 (1972).
16. Bursch W., Oberhammer F., Schulte-Harmann R., Trends Pharmacol. Sci., 13, 245-251 (1992).
17. Bonfoco E., Krainc D., Ankarcrona M., Nicotera P., Lipton S. A., Proc. Natl. Acad. Sci. U.S.A., 92, 7162-7166 (1995).
18. Leist M., Volbracht C., Kuhnle S., Fava E., Ferrando-May E., Nicotera P., Mol. Med., 3, 750-764 (1997).
19. Almeida A., Heales S. J., Bolanos J. P., Medina J. M., Brain Res., 790, 209-216 (1998).
20. Takada-Takatori Y., Kume T., Sugimoto M., Katsuki H., Sugimoto H., Akaike A., Neuropharmacology (in press).
21. Kume T., Sugimoto M., Takada Y., Yamaguchi T., Yonezawa A., Katsuki H., Sugimoto H., Akaike A., Eur. J. Pharmacol., 527, 77-85 (2005).
22. Takada Y., Yonezawa A., Kume T., Katsuki H., Kaneko S., Sugimoto H., Akaike A., J. Pharmacol. Exp. Ther., 306, 772-777 (2003).
23. Kihara T., Shimohama S., Sawada H., Honda K., Nakamizo T., Shibasaki H., Kume T., Akaike A., J. Biol. Chem., 276, 13541-13546 (2001).
24. Shaw S., Bencherif M., Marrero M. B., J. Biol. Chem., 277, 44920-44924 (2002).